Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients

Table 1 Patient demographics and tumor characteristics

Clinical parameter	Sorafenib	Control	P value2
No. of patients	34	68	-
Males	25	50	-
Age, yr1	48 (21-78)	57 (18-79)	0.142
Platelet count, 109/L1	121 (31-368)	156 (30-317)	0.046
Serum albumin, g/L1	38 (26-52)	36 (24-51)	0.387
Serum total bilirubin, mmol/L1	14.6 (5.1-48.3)	16.4 (7.6-51.5)	0.283
AST, IU/L1	56 (11-526)	59 (12-498)	0.525
Hemoglobin, g/L1	12.5 (6.6-18.6)	11.5 (5.9-17.3)	0.275
AFP ≥ 400, mg/L	23	45	0.882
Hepatitis B virus infection	29 (93.3%)	59 (92.0%)	0.692
ICG retention at 15 min, %1	7.7 (1.5-14.2)	7.3 (2.3-13.8)	0.482
Child–Pugh grade, A/B	27/7	54/14	-
HBV DNA, > 1/ ≤ 1 × 105 copy/mL	26/8	49/19	0.634
Prothrombin time, s1	14 (10-17)	14 (10-19)	0.224
Tumor size, cm1	6.4 (2.8-20.2)	5.9 (2.9-21.3)	0.098
Tumor number1	2 (1-8)	2 (1-10)	0.187
Hilar lymph nodes metastasis, yes/no	11/23	29/39	0.315
Liver cirrhosis, yes/no	30/4	60/8	-
ECOG performance status score, PS = 0/1	31/3	61/7	0.814
Median follow-up time, mo	26	25	-

¹Value expressed in median with range in parentheses;

²Study group compared with control group.